aDepartment of Oncology, Shanghai East Hospital, Tongji University, Shanghai, China bDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, ...

That approval was based on a phase 3 study that demonstrated a 46% reduction in the risk of disease progression or death, and a 27% reduction in the risk of death compared with Tecentriq alone. In ...

Presentations at the ASCO Annual Meeting 2026 illustrated a strengthening trend toward biomarker-driven, targeted first-line treatments for advanced and metastatic non-small cell lung cancers. Cancers ...

GSK’s oncology strategy had focused on gynecological and blood cancers, but the pharmaceutical company is striking deals that broaden its scope. It’s making a big move in lung cancer, announcing ...

Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to patients with first-line non-small cell lung cancer (NSCLC) has narrowed.

Scientists have identified proteins that could signal increased lung cancer risk, as well as a drug that could reduce the odds of a tumor developing. By Nina Agrawal Scientists have made a discovery ...

Eli Lilly and Co.’s cancer drug Retevmo has shown promise in helping patients combat a form of early-stage lung cancer, according to results from a late-stage clinical trial. The Indianapolis-based ...

At almost 83 years old, Barry Manilow's voice is raspier than his fans remember. "It's only been four months and they say it takes a year before you come back from something like that," he told ...

Ivonescimab combo cut risk of death by 34% versus Tevimbra Akeso touts ivonescimab as a potential new standard of care for patients Global trial comparing ivonescimab to Keytruda expected to aid US ...

An experimental lung cancer drug from Akeso and Summit Therapeutics improved survival in the Harmoni-6 Phase 3 trial conducted in China, according to results being presented at the American Society of ...

Chinese biopharma company Kelun-Biotech announced on Thursday that an antibody drug conjugate it is developing with Merck (MRK), with Keytruda, outperformed the U.S. drugmaker’s anti-PD-1 therapy in a ...